Literature DB >> 23628595

Improved sensitivity of point of care troponin I values using reporting to below the 99 th percentile of normals.

Hans G Schneider1, Patricia Ablitt2, James Taylor3.   

Abstract

INTRODUCTION: Troponin point of care tests have been found to have inferior sensitivity to laboratory based tests, when either the 10% CV or the 99 th percentile of a healthy population is used as the cut-off. In a prospective study we evaluated a decreased cut-off in the detection of cardiac injury.
METHODS: We compared 2 point of care assays (i-stat, Abbott Diagnostics and AQT 90, Radiometer) for troponin I with a laboratory assay for troponin I (ARCHITECT STAT troponin-I assay, Abbott Diagnostics), previously evaluated for diagnosis of acute coronary syndrome (ACS). We used the published 99 th percentile and a value that was 50% of that. We investigated these tests in a convenience sample of 195 patients presenting to a suburban hospital. We used chi-square tests for the comparison and a P<0.05 as significant. Clinical outcomes were obtained for patients with elevated levels of the laboratory assay.
RESULTS: At the 99 th percentile both assays did only detect cardiac injury in a percentage of true positives compared to the laboratory test (34 and 51%) with a significant rate of false negative values (19.6 and 14.9%). Using a decreased cut-off (50% of 99 th percentile) increased detection of true positives (to 80.9 and 76.5%) with an acceptable rate of false positive results (7.3 and 7.1%) significantly (P<0.01). Clinical review showed POC tests missed 6 of 13 patients with confirmed AMI (a sensitivity of 46%) and that a lower cut-off allowed them to detect all (for the i-stat) or most (4 of 6 for the AQT) of them. DISCUSSION: We believe that we have described in this study a way to improve the sensitivity of point of care assays for troponin that allows us to identify additional patients without losing the specificity required to identify appropriate patients for discharge from the emergency department. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  99th percentile; Acute coronary syndrome; Point of care; Troponin

Mesh:

Substances:

Year:  2013        PMID: 23628595     DOI: 10.1016/j.clinbiochem.2013.04.016

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  5 in total

Review 1.  [Cardiac troponins and beyond in acute coronary syndrome].

Authors:  M Vafaie; K M Stoyanov; H A Katus; E Giannitsis
Journal:  Internist (Berl)       Date:  2019-06       Impact factor: 0.743

2.  A prospective multi-centre study assessing the safety and effectiveness following the implementation of an accelerated chest pain pathway using point-of-care troponin for use in New Zealand rural hospital and primary care settings.

Authors:  Rory Miller; Garry Nixon; John W Pickering; Tim Stokes; Robin M Turner; Joanna Young; Marc Gutenstein; Michelle Smith; Tim Norman; Antony Watson; Peter George; Gerald Devlin; Stephen Du Toit; Martin Than
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2022-06-14

3.  The Usefulness and Limitations of Point-of-care Cardiac Troponin Measurement in the Emergency Department.

Authors:  Kenichiro Suzuki; Kimiaki Komukai; Kotaro Nakata; Ryeonshi Kang; Yuhei Oi; Eri Muto; Yusuke Kashiwagi; Mitsutoshi Tominaga; Satoru Miyanaga; Tetsuya Ishikawa; Kenji Okuno; Masahiko Uzura; Michihiro Yoshimura
Journal:  Intern Med       Date:  2018-02-09       Impact factor: 1.271

4.  Development of a Telemetric, Miniaturized Electrochemical Amperometric Analyzer.

Authors:  Jaehyo Jung; Jihoon Lee; Siho Shin; Youn Tae Kim
Journal:  Sensors (Basel)       Date:  2017-10-23       Impact factor: 3.576

5.  Implementation and evaluation of a rural general practice assessment pathway for possible cardiac chest pain using point-of-care troponin testing: a pilot study.

Authors:  Tim Norman; Joanna Young; Jo Scott Jones; Gishani Egan; John Pickering; Stephen Du Toit; Fraser Hamilton; Rory Miller; Chris Frampton; Gerard Devlin; Peter George; Martin Than
Journal:  BMJ Open       Date:  2022-04-15       Impact factor: 3.006

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.